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Abstract
Introduction  and  Objectives:  Left  ventricular  reverse  remodeling  (LVRR)  is strongly  related  to
the long-term  prognosis  of  patients  undergoing  cardiac  resynchronization  therapy  (CRT).  The
aim of  this  study  was  to  assess  the  long-term  clinical  outcome  of patients  without  LVRR  at  six
months after  CRT  implantation  and  to  determine  the  prognostic  impact  of  clinical  response  in
this population.
Methods:  We  analyzed  178  consecutive  patients  who  underwent  successful  CRT  device  implan-
tation (age  64±11  years;  69%  male;  89%  in  New  York  Heart  Association  [NYHA]  functional  class
III; 35%  with  ischemic  cardiomyopathy).  Clinical  status  and echocardiographic  parameters  were
determined before  and  six  months  after  CRT  implantation.  We  identified  those  without  crite-
ria for  LVRR  (≥10%  increase  in  left  ventricular  ejection  fraction  with  ≥15%  reduction  in  left
ventricular  end-systolic  diameter  compared  to  baseline).  Clinical  responders  were  defined  by
a sustained  improvement  of  at  least  one NYHA functional  class.
Results:  At  six-month  assessment  after  CRT,  109  (61%)  patients  showed  LVRR.  During  a  mean
follow-up of  56±21  months,  47  (26%)  patients  died,  with  higher  mortality  in the  group  without
LVRR (36%  vs.  20%,  p=0.023).  Clinical  response  was  greater  in patients  with  LVRR  (88%  vs.  55%,
p<0.001).  In  patients  without  LVRR,  clinical  response  to  CRT  was  the  strongest  independent
predictor of  survival  (hazard  ratio:  0.120;  95%  confidence  interval:  0.039-0.366;  p<0.001).
Conclusion:  Although  patients  without  LVRR  six  months  after  CRT  implantation  had  a  worse
prognosis,  with  higher  all-cause  mortality,  clinical  response  can  be an  independent  predictor  of
survival in this population.
©  2017  Sociedade  Portuguesa  de Cardiologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  All  rights
reserved.
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O  que  acontece  aos  não  respondedores  na terapia  de ressincronizac¸ão cardíaca?
Resumo
Introduc¸ão e  objetivos:  A  remodelagem  reversa  do ventrículo  esquerdo  (RRVE)  tem  sido forte-
mente relacionada  com  o  prognóstico  em  longo  prazo  de  doentes  submetidos  à  terapia  de
ressincronizac¸ão cardíaca  (TRC).  O  objetivo  deste  estudo  foi  avaliar  o  desfecho  clínico  a  longo
prazo de  doentes  sem  RRVE  aos  seis  meses  após  a  implantac¸ão  de  TRC  e definir  o impacto
prognóstico da  resposta  clínica  nessa  populac¸ão.
Métodos:  Foram  analisados  178  doentes  submetidos  à  implantac¸ão de  TRC  (64  ± 11  anos,  69%
do sexo  masculino,  89%  da  classe  funcional  III da  New  York  Heart  Association  (NYHA),  35%
com cardiomiopatia  isquémica).  O  estadio  clínico  e a  avaliac¸ão  ecocardiográfica  foram  feitos
antes e após  seis  meses  de TRC.  Foram  identificados  aqueles  que  não  tinham  critérios  de  RRVE
(aumento ≥  10%  na  frac¸ão  de ejec¸ão com  uma reduc¸ão de ≥ 15%  na  dimensão  sistólica  do
ventrículo esquerdo).  Os  respondedores  clínicos  foram  definidos  por  uma  melhoria  sustentada
de pelo  menos  uma  classe  funcional  NYHA.
Resultados:  Aos  seis  meses  de avaliac¸ão  após  TRC,  109  (61%)  doentes  apresentaram  RRVE.
Durante  um seguimento  médio  de  56  ± 21  meses,  47  (26%)  doentes  morreram,  com  maior  mor-
talidade  no grupo  sem  RRVE  (36%  versus  20%,  p  =  0,023).  A  resposta  clínica  foi maior  no grupo
de doentes  com  RRVE  (88%  versus  55%,  p  < 0,001).  Em  doentes  sem  RRVE,  a  resposta  clínica  à
TRC foi  o  maior  preditor  independente  de sobrevida  (hazard  ratio:  0,120;  IC95%:  0,039-0,366;
p <  0,001).
Conclusão:  Embora  doentes  sem  RRVE  seis  meses  após  a  implantac¸ão da  TRC  apresentem  um
pior prognóstico  com  maior  taxa  de  mortalidade  por  todas  as  causas,  a  resposta  clínica  pode
ser um  preditor  independente  de  sobrevida  nessa  populac¸ão.
© 2017  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Todos  os
direitos reservados.
List  of  abbreviations
AV  atrioventricular
BMI  body  mass index
CRT  cardiac  resynchronization  therapy
HF  heart  failure
LBBB  left  bundle  branch  block
LVEDD  left  ventricular  end-diastolic  diameter
LVEF  left  ventricular  ejection  fraction
LVESV  left  ventricular  end-systolic  volume
LVRR  left  ventricular  reverse  remodeling
NYHA  New  York  Heart  Association
VV  interventricular
Introduction
Cardiac  resynchronization  therapy  (CRT)  is  recommended  by
current  guidelines  for  symptomatic  heart  failure  (HF)  with
left  ventricular  ejection  fraction  (LVEF)  ≤35%  and prolonged
QRS  interval.1,2 CRT  is  effective  in  improving  HF  symptoms,
exercise  capacity,  quality  of life  and  cardiac  function,  as
well  as  reducing  HF hospitalizations  and  death.3--8 Trials
have  assessed  the efficacy  of  CRT by  means  of improvement
in  clinical  status  and/or  reduction  in  left ventricular  end-
systolic  volume  (LVESV)  at  mid-term  follow-up.9--12 Clinical
and  echocardiographic  responses  to  CRT  may  not coincide,
but  left ventricular  reverse  remodeling  (LVRR)  is  consid-
ered  a  powerful  indicator  of clinical  outcomes.13--15 Up  to
40%  of  patients  will  not  experience  significant  reduction  in
left  ventricular  chamber  size  and  are  defined  as  CRT  non-
responders.16 Although  this  population  has  a  poor prognosis,
little  is  known  about  the factors  that  influence  their  out-
comes.  The  aim  of  this  study  was  to  assess  the long-term
clinical  outcome  of  patients  without  LVRR  at  six months  after
CRT  implantation  and to  determine  the  prognostic  impact  of
clinical  response  in  this  population.
Methods
This was  a  single-center  study  of  patients  who  underwent
successful  CRT  defibrillator  device implantation  between
2004  and  2012,  a total  of  178 consecutive  CRT  recipients.
Patient  data  were  prospectively  collected  in  our cardiology
department’s  information  system  and  analyzed  retrospec-
tively.  Patients  were  selected  for  CRT  if they  met  currently
recommended  criteria:  (1)  LVEF  ≤35%;  (2)  symptoms  of  HF,
defined  as  New York  Heart  Association  (NYHA)  class  II-IV
despite  optimal  medical  therapy;  and  (3)  QRS  duration  ≥120
ms.  Patients  were  classified  as  ischemic  in the  presence  of
significant  coronary  artery  disease  (>50%  stenosis  of  two  or
more  epicardial  vessels  or  the left main,  or  >50%  stenosis
of  the  proximal  left  anterior  descending  coronary  artery  on
coronary  angiography,  and/or  a  history  of  previous  myocar-
dial  infarction  or  myocardial  revascularization).  All other
patients  were  classified  as  non-ischemic.  Leads  were  placed
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transvenously,  via the  subclavian  and cephalic  route,  using
fluoroscopy  to  visualize  their  progression  and location.  The
right  ventricular  lead  was  positioned  in the apex  or  mid
septum.  The  left ventricular  lead  was  placed  with  an over-
the-wire  system  in a  posterolateral  or  lateral  tributary  vein
of  the  coronary  sinus  depending  on  ability  to  cannulate  the
veins,  pacing  threshold,  or  diaphragmatic  stimulation.  The
standard  settings  included  an atrioventricular  (AV)  delay
of  100  ms (sensed)  and  130 ms  (paced),  with  DDD  or
DDDR  mode  and  standard  lower  (50  beats/min)  and upper
(120-130  beats/min)  pacing  rates.  Extensive  demographic
and  clinical  data, including  mortality,  NYHA  class  and  hos-
pitalization  for worsening  HF were  collected  from  medical
records.  Clinical  response  to  CRT was  defined  as  a  sustained
improvement  of  ≥1  NYHA  functional  class  at six-month
follow-up.  Transthoracic  two-dimensional  echocardiogra-
phic  information  was  assessed  at  baseline  and  six months
after  CRT  device  implantation.  LVRR  was  defined  as  an
increase  of  ≥10%  in LVEF  over baseline  combined  with  ≥15%
reduction  in  left ventricular  end-systolic  diameter  (LVESD).
Cardiac  structure  and  function  were assessed  using  a com-
mercially  available  ultrasound  system  (Vivid-7  and Vivid-E9;
GE  Vingmed  Ultrasound,  Horten,  Norway)  equipped  with
a  3.5-MHz  transducer.  LVESD,  left  ventricular  end-diastolic
diameter  (LVEDD)  and LVEF  were  determined  according  to
standard  techniques  and  digitally  stored  for  offline  analy-
sis  in  cine-loop  format.  Echocardiographic  CRT  optimization
was  performed  if  patients  presented  AV  and/or  interven-
tricular  (VV)  dyssynchrony.17 Optimization  was  based  on
the  iterative  method,  analyzing  changes  in left ventricular
inflow  and  outflow,  while  AV  and/or  VV  delays  were  changed
in  10-  or  20-ms  steps.
Follow-up  data  were  obtained  by  review  of  medical
records,  outpatient  clinic  visits,  and  telephone  contact.
Ethics  committee  and  hospital  permission  were  obtained
from  the  appropriate  local  authorities.
Statistical  analysis
Data  are  expressed  as  mean  ±  standard  deviation  for  con-
tinuous  variables  and as  frequencies  and  percentages  for
categorical  variables.  Data  distribution  was  tested  for  nor-
mality  using  the  Kolmogorov-Smirnov  or  Shapiro-Wilk  test  as
appropriate.  Missing  patient-level  covariates  were  assumed
to  be  missing  and  no  imputation  was  performed.  Com-
parisons  of baseline  characteristics  and outcomes  were
performed  using  the  chi-square  test  or  Fisher’s  exact  test,
as  appropriate,  for  categorical  variables  and  the Student’s
t  test  or  the  Mann-Whitney  test  for continuous  variables.
Cumulative  event  rates after  CRT device  implantation  were
calculated  using the Kaplan-Meier  method  and  the pop-
ulation  without  LVRR  was  classified  according  to  clinical
response.  Log-rank  tests  for  time-to-event  data  with  respect
to  all-cause  mortality  were  used  for statistical  comparison
between  the  patient  groups.  Multivariate  Cox proportional
hazards  models  were constructed  with  backward  selection
to  identify  independent  predictors  of  all-cause  mortality.  All
significant  univariate  clinical  and  echocardiographic  predic-
tors  at  baseline  and  hospitalizations  for  HF  during  follow-up
were  entered  in  the multivariate  model  as  covariates.  All
statistical  tests  were  two-sided,  and a p-value  <0.05  was
considered  significant.  SPSS  version  21  software  (IBM  SPSS
Inc.,  Chicago,  IL)  was  used  for  computation.
Results
Baseline  patient  characteristics
The  study  population  consisted  of  178 consecutive  patients
who  underwent  successful  CRT device  implantation  (age
64±11  years;  69%  male).  Baseline  patient  characteristics  are
shown  in Table  1. Sixty-nine  patients  (39%)  failed  to  show an
increase  of  ≥10%  in LVEF  and  ≥15%  reduction  in  LVESD  at
six-month  follow-up  (non-LVRR  group).  The  majority  of  the
cohort  (65%) had  non-ischemic  cardiomyopathy.
Regarding  differences  between  the  groups, patients  with-
out LVRR  tended  to  be male  (83%  vs.  61%  p=0.003),  to  have
ischemic  cardiomyopathy  (49%  vs.  26%, p=0.002)  and  to  show
more  severe  baseline  HF  (NYHA  ≥III  83%  vs.  97%,  p=0.01).
Also,  no  LVRR  after  CRT  was  associated  with  smoking  (47%  vs.
25%,  p=0.004),  lower  body  mass  index  (BMI)  (26  vs.  28  kg/m2,
p=0.042),  previous  heart surgery  (30%  vs.  13%, p=0.006),
renal  dysfunction  (46%  vs.  27%,  p=0.017),  higher  LVEDD
(77  vs.  72  mm,  p=0.003)  and  LVESD  (63  vs.  51  mm  p<0.001),
and  reduced  LVEF (24%  vs.  26%,  p=0.037).  On the other  hand,
CRT  response  was  associated  with  sinus  rhythm  (73%  vs.  42%,
p<0.001)  and  with  left  bundle  branch  block  (LBBB) (89%  vs.
72%,  p=0.007).
Clinical  outcomes  in  the overall  population
During  a mean  follow-up  of  56±21  months,  47  (26%)  patients
died,  21  (45%) due  to  cardiac  causes,  45  (25%)  patients  were
hospitalized  due  to  HF,  and  70  (39%) patients  died  or  were
hospitalized  due  to  HF.
Five-year  overall  mortality  was  39.2%,  two-year  mortality
was  12.6%  and one-year  mortality  was  6.7%. Annual  mor-
tality  was  7.8%  overall.  The  group  with  no LVRR  showed
higher  mortality  (36%  vs.  20%, p=0.023),  with  more  deaths
of  cardiac  cause  (23%  vs.  5%,  p=0.001),  and  higher  rates  of
hospitalizations  due  to  HF (48%  vs.  11%,  p<0.001).  Clinical
response  was  found  to  be greater  in the LVRR  group  (88%  vs.
55%,  p<0.001).
Patients  without  left  ventricular  reverse
remodeling
There  were  thirty-eight  patients  (55%) with  an improve-
ment  of  ≥1 NYHA  functional  class  (clinical  response  to
CRT)  among  the 69  patients  without  LVRR.  Mean  NYHA  class
improved  from  2.86±0.46  at  implantation  to  2.19±0.71
at  six-month  follow-up  (p<0.001,  95%  confidence  inter-
val  [CI],  0.50-0.83).  No  difference  was  observed  between
ischemic  and  nonischemic  cardiomyopathy  (p=0.81).  Com-
parison  of clinical  and  echocardiographic  data  between  the
two  groups  (clinical  responders  vs. non-responders  among
patients  without LVRR)  at  six-month  follow-up  are shown  in
Table  2.  There  were  no  differences  between  the  groups  in
age,  gender,  baseline  NYHA  class,  BMI,  history  of  diabetes
or  smoking,  atrial  fibrillation,  renal  dysfunction,  previ-
ous  heart  surgery,  prevalence  of  LBBB,  QRS  duration,  left
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Table  1  Baseline  clinical  and  echocardiographic  characteristics.
Baseline  All  patients  (n=178)  LVRR  (n=109)  No  LVRR  (n=69)  p
Age,  years,  mean  ±  SD 64±11 64±11  64±10  0.880
Male gender,  n (%)  123  (69)  66  (61)  57  (83)  0.003
Ischemic etiology,  n  (%)  62  (35)  28  (26)  34  (49)  0.002
NYHA class,  mean  ± SD 2.9±0.4  3.0±0.3  2.9±0.5  0.010
NYHA class  ≥III,  n  (%)  165  (93)  106 (97)  59  (86)  0.016
Weight, kg,  mean  ±  SD  76±13  76±14  75±13  0.609
BMI, kg/m2,  mean  ±  SD  27±4  28±4  26±4  0.042
Obesity,  n  (%)  44  (25)  33  (30)  11  (16)  0.058
Hypertension,  n  (%) 136  (76) 86  (79) 50  (73)  0.358
Dyslipidemia,  n  (%) 100  (56) 64  (59) 36  (52) 0.433
Diabetes, n (%) 59  (33) 36  (33) 23  (33) 1.000
History of  smoking,  n  (%)  59  (33)  26  (24)  33  (48)  0.004
COPD, n  (%)  33  (19)  17  (16)  16  (23)  0.303
Previous heart  surgery,  n  (%)  35  (20)  14  (13)  21  (30)  0.006
Prosthetic  valve,  n (%)  15  (8) 8 (7)  7  (10)  0.584
Creatinine,  mg/dl,  mean  ±  SD 1.17±0.55  1.13±0.52  1.26±0.59  0.170
CrCl, ml/min/1.73  m2, mean  ± SD  75±33  77±34  70±30  0.164
CrCl <60  ml/min/1.73  m2, n (%)  61  (34)  29  (27)  32  (46)  0.017
Sinus rhythm,  n  (%)  108  (61)  79  (73)  29  (42)  <0.001
LBBB, n  (%)  147  (83)  97  (89)  50  (72)  0.007
QRS duration,  ms,  mean  ±  SD  167±30  170±29  162±32  0.104
QRS duration  >150  ms,  n  (%)  129  (72)  81  (74)  47  (68)  0.191
LVEDD,  mm,  mean  ±  SD  74±10  72±10  77±9  0.003
LVESD, mm,  mean  ±  SD  56±12  51±12  63±11  <0.001
LVEF, %,  mean  ± SD  25±7  26±7  24±6  0.037
ICD, n  (%)  163  (92)  101 (93)  62  (90)  0.584
Clinical response,  n  (%)  134  (75)  96  (88)  38  (55)  <0.001
Follow-up,  months,  mean  ± SD  56±31  72±27  35±21  <0.001
All-cause  mortality,  n  (%)  47  (26)  22  (20)  25  (36)  0.023
Cardiac death,  n  (%) 21  (12)  5 (5)  16  (23)  0.001
Hospitalization  for  HF,  n  (%) 45  (25) 12  (11)  33  (48)  <0.001
All-cause  mortality  and/or  hospitalization  for  HF,  n (%) 70  (39)  31  (28)  39  (56)  <0.001
BMI: body mass index; COPD: chronic obstructive pulmonary disease; CrCl: creatinine clearance; HF: heart failure; ICD: implantable
cardioverter-defibrillator; LBBB: left bundle branch block; LVEDD: left ventricular end-systolic diameter; LVEF: left ventricular ejection
fraction; LVESD: left ventricular end-diastolic diameter; LVRR: left ventricular reverse remodeling; NYHA: New York Heart Association.
ventricular  dimensions  or  systolic  function,  baseline  mitral
regurgitation  or echocardiographic  CRT optimization  dur-
ing  follow-up.  Twenty-five  (36%)  patients  died,  with  higher
mortality  in the non-responders  (58%  vs. 18%,  p=0.001).
Thirty-three  patients  (48%)  were  hospitalized  due  to  HF  (58%
vs.  40%,  p=0.151)  and  24  patients  (35%)  received  appropri-
ate  therapies  for  ventricular  tachyarrhythmias  (26%  vs.  46%,
p=0.126).
Clinical  response,  mortality  and hospitalizations
due  to heart  failure
Non-responders  to  CRT  among  patients  without  LVRR  was  sig-
nificantly  associated  with  all-cause  mortality,  cardiac  death
and  the  combined  endpoint  (all-cause  mortality  and hospi-
talization  due  to  HF).  When  the population  was  classified
according  to  clinical  response  to  CRT,  a cumulative  3%,  4%,
and  10%  of  the patients  with  improvement  of  ≥1  NYHA
functional  class died  at 12-,  24-, and  36-month  follow-
up,  respectively.  In  contrast,  10%,  29%,  and  52%  of the
patients  without improvement  of  ≥1  NYHA  functional  class
died  during  the  same  period,  respectively  (log-rank  p<0.001,
Figure  1A).  Also,  a cumulative  11%,  18%,  and 38%  of  the
patients  with  improvement  of  ≥1  NYHA  functional  class  had
the  combined  endpoint  by  12-, 24-,  and 36-month  follow-up,
respectively,  and  32%,  54%,  and 67%  of  the patients  without
improvement  of  ≥1  NYHA  functional  class  had the com-
bined  endpoint  during  the same  period  (log-rank  p=0.002,
Figure  1B).
To determine  whether  clinical  response  in patients
without  LVRR  was  an independent  predictor  of  all-cause
mortality  during  follow-up,  univariate  predictors  with  a
p-value  <0.05  were  entered  into  a Cox  proportional
hazards  model  as  covariates  (Table  3). On  multivari-
ate  analysis,  clinical  response (hazard  ratio  [HR]:  0.120;
95%  CI: 0.039-0.366;  p<0.001)  was  independently  associ-
ated  with  better  survival.  Reduced  LVEF  at baseline  (HR:
4.768;  95%  CI:  1.487-15.293;  p=0.009),  significant  mitral
regurgitation  (grade  >2+)  post-CRT  (HR:  2.863;  95%  CI:
1.139-7.196;  p=0.025)  and  hospitalization  due  to  HF  within
12  months  of follow-up  (HR:  2.459;  95%  CI: 1.030-5.870;
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Table  2  Clinical  and  echocardiographic  characteristics  according  to  clinical  response  in patients  without  left  ventricular  reverse
remodeling.
Baseline  Clinical  responders  (n=38)  Non-responders  (n=31)  p
Age,  years,  mean  ± SD  64±11  64±10  0.823
Male gender,  n  (%)  31  (82)  26  (84)  1.000
Ischemic etiology,  n  (%)  18  (48)  16  (52)  0.811
NYHA class,  mean  ± SD  2.95±0.40  2.74±0.51  0.074
NYHA class  ≥III,  n  (%)  34  (90)  25  (81)  0.327
BMI, kg/m2,  mean  ± SD 26±4  27±4  0.151
Obesity, n  (%)  5  (13)  6  (19)  0.525
Diabetes, n  (%) 15  (40) 8  (26) 0.307
History  of  smoking,  n  (%) 16  (42) 17  (54) 0.456
COPD, n  (%) 7  (18) 9  (29) 0.379
AF, n  (%)  20  (53)  16  (52)  1.000
CrCl, ml/min/1.73  m2, mean  ± SD 72±30  67±30  0.317
CrCl <60  ml/min/1.73  m2, n  (%)  14  (37)  18  (58)  0.094
Previous heart  surgery,  n  (%)  9  (24)  12  (39)  0.199
LBBB, n  (%)  29  (76)  21  (68)  0.589
QRS duration,  ms,  mean  ±  SD  158±30  167±35  0.398
QRS duration  >150  ms, n (%)  25  (66)  22  (70)  0.794
LVEDD, mm,  mean  ± SD  76±9  77±9  0.792
LVESD, mm,  mean  ±  SD  62±9  63±10  0.912
LVEF, %,  mean  ±  SD  23±6  25±6  0.401
MR grade  3+  or  4+,  n  (%)  10  (26)  8  (26)  1.000
CRT optimization,  n  (%)  10  (26)  8  (26)  1.000
Follow-up, months,  mean  ± SD  40±23  30±18  0.051
Appropriate therapies,  n  (%)  17  (46)  8  (26)  0.126
All-cause mortality,  n (%) 7  (18)  18  (58)  0.001
Cardiac death,  n  (%)  3  (8) 13  (42)  0.001
Hospitalization  for  HF,  n  (%)  15  (40)  18  (58)  0.151
All-cause mortality  and/or  hospitalization  for  HF,  n  (%)  15  (40)  22  (71)  0.015
AF: atrial fibrillation; Appropriate therapies: antitachycardia pacing and/or shock; BMI: body mass index; COPD: chronic obstructive
pulmonary disease; CrCl: creatinine clearance; CRT: cardiac resynchronization therapy; HF: heart failure; LBBB: left bundle branch block;
LVEDD: left ventricular end-systolic diameter; LVEF: left ventricular ejection fraction; LVESD: left ventricular end-diastolic diameter;
MR: mitral regurgitation; NYHA: New York Heart Association.
p=0.043)  were  associated  with  higher  all-cause  mortal-
ity.
As  expected,  the  main  cause  of  mortality  was  cardiac
death  (16  out of  25  patients).  Interestingly,  non-responders
died  more  frequently  for  cardiovascular  reasons  compared
with  responders,  although  this was  not  statistically  signifi-
cant  (13  [72%]  vs.  3 [43%],  p=0.205).
Discussion
The major  findings  of the present  study,  which  focused  on
the  prognostic  impact  of  clinical  response  to CRT  in  patients
without  LVRR  six months  after  CRT,  are:  first,  the  majority
of  patients  (61%)  presented  evidence  of  LVRR;  second,  the
overall  clinical  response rate  was  75%; third,  patients  with
LVRR  had  higher  survival  rates and less  hospitalizations  due
to  HF;  fourth,  among  patients  without  LVRR,  55%  presented
long-term  improvement  of  ≥1  NYHA  functional  class;  fifth,
clinical  response  was  the strongest  independent  predictor
of  survival  in  patients  without  LVRR.
Several  studies  have  confirmed  the  favorable  impact
on  mortality  and  morbidity  of  CRT  in  mid-  to  long-term
follow-up.6--12 In  our  cohort,  patients  with  LVRR  showed
better  clinical  outcomes,  with  higher  survival  rates (80%
vs.  64%, p=0.023)  and  less  hospitalizations  due  to  HF  (11%
vs.  48%,  p<0.001).  This  survival  benefit  may  be related  to
the  occurrence  and  extent  of  LVRR  in  mid-term  follow-
up,  rather  than  to  improvement  in NYHA  functional  class,
according  to other  authors.12--16,18--20 Results  of  the REVERSE,
MADIT-CRT,  and RAFT  trials  showed that  reduction  in HF
readmissions  and improvement  in long-term  survival  appear
to  be related  to  LVRR  and improvement  of left ventricular
performance  rather than  improvements  in NYHA  func-
tional  class,  since  the patients  included  were  asymptomatic
or  only mildly  symptomatic.12,18,19 Yu et  al.13 showed  in
141  HF  patients  that  reductions  of ≥10%  in LVESV  were inde-
pendently  associated  with  mid-term  outcome  after CRT  and
that  improvement  in clinical  parameters  was  not  predictive
of  long-term  survival.  In a  retrospective  and non-randomized
study,  Bertini  et al.20 concluded  that  reduction  in LVESV  in
mid-term  follow-up  was  a better  predictor  of long-term  sur-
vival  than  improvement  in  clinical  status.
According  to  these  data,  LVRR  should  be a more  suit-
able  surrogate  to  assess  the  efficacy  of  CRT  than  subjective
clinical  parameters.  Unfortunately,  there  are  a signifi-
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Figure  1  Kaplan-Meier  curves  of  all-cause  mortality  and
hospitalizations  due  to  heart  failure.  (A)  The  probability
of all-cause  mortality  differed  significantly  between  clinical
responders  and  non-responders;  (B)  the  probability  of  all-cause
mortality  and  hospitalizations  due to  heart  failure  differed  sig-
nificantly  between  clinical  responders  and  non-responders.
cant  proportion  of  non-responders  to  CRT,  ranging  between
17  and  46%,  depending  on  the  criteria  used.21 In our
study,  39%  of  patients  did not  present  LVRR.  The  factors
mainly  identified  as  contributors  to  lack  of  response  to
CRT  are ischemic  etiology,  shorter  QRS  duration  and  less
baseline  mechanical  dyssynchrony.22--24 We also  found  that
non-ischemic  cardiomyopathy  (74%  vs.  51%, p=0.002)  and
LBBB  (89% vs.  72%,  p=0.007)  were  associated  with  LVRR.
QRS  duration  was  not found  to  be  statistically  associated
with  LVRR,  probably  due  to  the size  of  our study  popula-
tion.  Female  gender  was  associated  with  LVRR  (39%  vs.  17%,
p=0.003),  in agreement  with  previous  studies.25,26
In  the present  study,  75%  of  patients  referred  for  CRT
presented  a  clinical  response in long-term  follow-up.  This
higher  rate  of clinical  response  compared  to  LVRR  is  in
line  with  previous  studies,  in which  clinical  responders
range  between  61%  and  77%,23,27--29 with  a  mean  of 66.9%.30
Although  improvement  in NYHA  functional  class  and  LVRR
are  connected,  the concordance  between  the  two  response
types  is  not  perfect.24 In  the present  study,  28%  of  patients
(38  out  of  134)  with  clinical  improvement  did not have  LVRR.
Previous  studies  found  similar  results,  with  a  rate  of  dis-
agreement  of around  28%.25,29--32 The  follow-up  profile  in the
presence  of  clinical  improvement  without  LVRR  is  not  well
known.  It  has  been  questioned  whether  this  change  is  due
to  a placebo  effect  or  should also  be considered  a  positive
response  to  CRT.  Patients  with  improvement  of  ≥1  NYHA
class  among  those  without  LVRR  at six months  after  CRT
showed  lower  all-cause  mortality  (18%  vs.  58%, p=0.001).
Also,  on  multivariate  analysis,  clinical  response  was  inde-
pendently  associated  with  better  survival  (HR:  0.120,  95%
CI: 0.039-0.366,  p<0.001).
These  conflicting  findings,  which  contrast  with  previ-
ously  reported  results,  should  be interpreted  with  caution
because  of  the  retrospective  nature  of the  analysis  and
the size  of  the study  population.  Despite  this,  our  results
show  some similarities  with  published  data.  In  a study of
174  HF  patients,  Kronborg  et  al.33 found  that clinical
response  to  CRT  was  an independent  predictor  of  mortal-
ity  in very  long-term  follow-up  (HR:  3.02,  95%  CI:  1.71-5.38,
p<0.001).  Improvement  in  functional  class  was  addressed  by
another  study with  a different  methodology,  which  showed
that  self-assessed  functional  class  two  months  after  CRT was
a  strong  predictor  of long-term  survival  (HR:  0.59,  95%  CI:
0.40-0.87,  p<0.007).34 These  studies  show that  symptomatic
response  after  CRT is  associated  with  better survival  and
Table  3  Cox  univariate  and multivariate  regression  analysis  for  all-cause  mortality.
Dependent  variable:  all-cause  mortality  Univariate  analysis  Multivariate  analysis
HR  (95%  CI) p  HR  (95%  CI)  p
Age,  years  1.035  (1.007-1.080)  0.043  -  -
Renal dysfunction  3.861  (1.603-9.299)  0.003  -  -
LVEF <20%  2.046  (1.056-4.681)  0.029  4.768  (1.487-15.293)  0.009
MR post-CRT,  grade  3+  or  4+  2.081  (1.105-4.664)  0.041  2.863  (1.139-7.196)  0.025
RV dysfunction  3.117(1.199-8.101)  0.020  -  -
Clinical response  0.205  (0.084-0.501)  0.001  0.120  (0.039-0.366)  <0.001
Hospitalization  for  HF  within  12  months  of  follow-up  3.102  (1.405-6.852)  0.005  2.459  (1.030-5.870)  0.043
CI: confidence interval; CRT: cardiac resynchronization therapy; HF: heart failure; HR: hazard ratio; LVEF: left ventricular ejection
fraction; MR: mitral regurgitation; RV: right ventricular.
Renal dysfunction: glomerular filtration rate <60 ml/min/1.73 m2.
RV dysfunction: tricuspid annular plane systolic excursion <16 mm or velocity of  tricuspid annular systolic motion by tissue Doppler
imaging <9.5 cm/s.
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are  consistent  with  data  previously  described  by  Molhoek
et  al.35 and  Cha  et  al.36 Moreover,  the low  annual  mortality
in  our  population  (≈8%)  confirms  the synergistic  interac-
tion  between  administration  of  neurohumoral  antagonists,
CRT,  and  cardioverter-defibrillator  implantation  in a  daily
practice  setting.
Lower  LVEF  at  baseline  was  also  related  to  mortality  in
our  study.  This is  supported  by  a large  multicenter  prospec-
tive  study.37 In addition,  significant  mitral  regurgitation
(grade  >2+)  post-CRT  was  found  to  be  independently  asso-
ciated  with  all-cause  mortality,  as  also  described  in the
Cardiac  Resynchronization  in  Heart  Failure  Trial38 and by  van
Bommel  et  al.39 Another  clinical  parameter  with  impact  on
mortality  was  hospitalization  due  to  HF  during  the first year
of  follow-up.  The  importance  of  HF  admissions  after CRT was
also  shown  by  Bertini  et  al.,20 and  data  from  the MADIT-CRT
trial  revealed  an association  between  future  events  and  HF
admission  during  the 12  months  before  CRT  implantation.40
Finally,  these  data  indicate  that  lack  of  clinical  improve-
ment  in  patients  without LVRR  after  CRT  was  a strong  marker
of  worse  prognosis.  Its  effect  was  independent  of  age,  renal
function  and  right  ventricular  dysfunction.
Limitations
This  was  a  retrospective,  single-center,  non-randomized  and
non-controlled  study,  and this  should  be  taken  into  con-
sideration  when  interpreting  the results.  Notwithstanding,
this  represents  a  real-life  group  of  patients  followed  in a
referral  center.  Secondly,  clinical  response  was  based  on
improvement  in NYHA  class  and did not  include  assess-
ment  of  functional  capacity  or  quality  of  life  scores.
Thirdly,  clinical  and  echocardiographic  response  was  con-
sidered  at  six-month  follow-up,  but  some  patients  may  have
had  late  LVRR.41 Fourthly,  there  will always  be  a  certain
degree  of  intra-  and  inter-observer  variability  in  analysis
of  echocardiographic  parameters,  whatever  the  operator’s
expertise.  Fifthly,  other  parameters  such  as position  of
the  left  ventricular  lead,  device programming,  presence
of  rhythm  abnormalities,  extent  of  myocardial  scar  and
brain  natriuretic  peptide  levels  were  not  addressed  in
this  study.  Finally,  due  to  the small  number  of patients
included  in  the  study,  its  findings  regarding  predictors  of  all-
cause  mortality  need  confirmation  in large-scale  prospective
studies.
Conclusions
HF patients  treated  with  CRT without  LVRR  at mid-term
follow-up  had  a  worse  long-term  prognosis  than  patients
with  LVRR,  with a high  rate  of hospitalizations  due  to  HF  and
all-cause  mortality.  However,  among  these  patients,  clini-
cal  response  appeared  to be  independently  associated  with
better  survival.  Further  studies  are needed to  clarify  the
prognostic  impact  of a sustained  clinical  response  in the
absence  of  LVRR  following  CRT.
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